// App-Quantinova.ai

AB1121 (2022) : HOW FEARS AND HOPES HAVE EVOLVED IN PATIENTS WITH RMDs THROUGHOUT THE COVID-19 PANDEMIC? RESULTS FROM THE REUMAVID STUDY (PHASE 1 AND 2)

Researchers

Presenter

  • M. Garrido-Cumbrera

Principal Investigators

  • H. Marzo-Ortega

  • L. Christen

  • J. Correa-Fernndez

  • E. Mateus

  • L. Grange

  • D. Webb

  • C. Jacklin

  • S. Irwin

  • S. Mingolla

  • K. Antonopoulou

  • S. Makri

  • V. Navarro-Compn

Medical Centers

  • Health & Territory Research, Universidad de Sevilla, Seville, Spain, Sevilla

  • Spanish Federation of Spondyloarthritis Patient Associations (CEADE), Patient Advocacy, Madrid, Spain

  • NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Novartis Pharma AG, Patient Engagement, Basel, Spain

  • Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Management, Lisbon, Portugal

  • NOVA Medical School—Comprehensive Health Research Center (CHRC), Lisbon, Portugal

  • French League Against Rheumatism (AFLAR), Patient Advocacy, Paris, France

  • Centre Hospitalier Universitaire de Grenoble Alpes/ hôpital sud Grenoble, Rheumatology Department, Grenoble, France

  • National Axial Spondyloarthritis Society (NASS), Patient Advocacy, London, United Kingdom

  • National Rheumatoid Arthritis Society, Maidenhead, United Kingdom

  • Arthritis Action, Patient Advocacy, London, United Kingdom

  • Italian National Association of People with Rheumatic and Rare Diseases (APMARR), Patient Advocacy, Lecce, Italy

  • Hellenic League Against Rheumatism (ELEANA), Patient Advocacy, Athens, Greece

  • Cyprus League for People with Rheumatism (CYLPER), Patient Advocacy, Nicosia, Cyprus

  • Hospital Universitario La Paz, Madrid, Spain

Locations

  • Spain

  • United Kingdom

  • Switzerland

  • Portugal

  • France

  • Italy

  • Greece

  • Cyprus

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Central Nervous System (CNS)

Disease

  • Depression

  • Coronavirus disease

  • Anxiety

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multinational

  • Cross-Sectional

Phase

  • I

Study Id's

  • N/A

Sponsors

  • Novartis Pharma

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved